Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
复制标题
DOI：
10.1016/s0140-6736(20)31304-0
复制
发表时间：
2020-08-01
期刊：
影响因子：
168.9
通讯作者：
Guessous, Idris
中科院分区：
文献类型：
--
作者：
Stringhini, Silvia;Wisniak, Ania;Guessous, Idris
背景考虑到新冠肺炎对检测策略、改变的病例定义和疾病陈述的依赖，基于医疗救治病例数量来评估其负担并不理想。以人群为基础的血清调查测量抗严重急性呼吸综合征冠状病毒2(抗SARS-CoV-2)抗体提供了一种估计感染率和监测疫情发展的方法。在这里，我们估计了在疫情期间，瑞士日内瓦人群中抗SARS-CoV-2抗体的每周血清阳性率。方法SEROCoV-POP研究是一项以人群为基础的研究，对象是前Bus Sante研究参与者及其家庭成员。我们计划在之前的人群代表性调查中随机选择参与者及其5岁及以上的家庭成员进行一系列连续12周的血清调查。我们使用一种商用的酶联免疫吸附试验检测了每个参与者的抗SARS-CoV-2-Ig G抗体。我们使用贝叶斯Logistic回归模型估计了血清阳性率，考虑了测试表现，并根据日内瓦人口的年龄和性别进行了调整。在这里，我们展示了前5周的研究结果。在2020年4月6日至5月9日期间，我们招募了来自1339个家庭的2766名参与者，其人口分布类似于日内瓦。在第一周，我们估计4中心点的血清阳性率为8%(95%CI 2中心点4-8中心点0，n=341)。第二周增加到8个中心点5%(5个中心点9~11个中心点4，n=469)，第三周增加到10个中心点9%(7个中心点9~14个中心点4，n=577)，4周6个中心点6%(4个中心点3~9个中心点4，n=604)，第五周10个中心点8%(8个中心点2~13个中心点9，n=775)。5~9岁(相对危险度[RR]0中心点32[95%CI 0中心点11~0中心点63])和65岁以上人群(RR 0中心点50[0中心点28~0中心点78])的血清阳性风险显著低于20~49岁人群。在考虑了血清转换的时间后，我们估计，每报告一个确诊病例，社区中就有11个中心点6感染。解释这些结果表明，在这波大流行期间，日内瓦的大多数人口没有受到感染，尽管新冠肺炎在该地区的流行率很高(报告的临床病例超过5,000例
Background Assessing the burden of COVID-19 on the basis of medically attended case numbers is suboptimal given its reliance on testing strategy, changing case definitions, and disease presentation. Population-based serosurveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating infection rates and monitoring the progression of the epidemic. Here, we estimate weekly seroprevalence of anti-SARS-CoV-2 antibodies in the population of Geneva, Switzerland, during the epidemic.Methods The SEROCoV-POP study is a population-based study of former participants of the Bus Sante study and their household members. We planned a series of 12 consecutive weekly serosurveys among randomly selected participants from a previous population-representative survey, and their household members aged 5 years and older. We tested each participant for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA. We estimated seroprevalence using a Bayesian logistic regression model taking into account test performance and adjusting for the age and sex of Geneva's population. Here we present results from the first 5 weeks of the study.Findings Between April 6 and May 9, 2020, we enrolled 2766 participants from 1339 households, with a demographic distribution similar to that of the canton of Geneva. In the first week, we estimated a seroprevalence of 4 center dot 8% (95% CI 2 center dot 4-8 center dot 0, n=341). The estimate increased to 8 center dot 5% (5 center dot 9-11 center dot 4, n=469) in the second week, to 10 center dot 9% (7 center dot 9-14 center dot 4, n=577) in the third week, 6 center dot 6% (4 center dot 3-9 center dot 4, n=604) in the fourth week, and 10 center dot 8% (8 center dot 2-13 center dot 9, n=775) in the fifth week. Individuals aged 5-9 years (relative risk [RR] 0 center dot 32 [95% CI 0 center dot 11-0 center dot 63]) and those older than 65 years (RR 0 center dot 50 [0 center dot 28-0 center dot 78]) had a significantly lower risk of being seropositive than those aged 20-49 years. After accounting for the time to seroconversion, we estimated that for every reported confirmed case, there were 11 center dot 6 infections in the community.Interpretation These results suggest that most of the population of Geneva remained uninfected during this wave of the pandemic, despite the high prevalence of COVID-19 in the region (5000 reported clinical cases over